Intellia Therapeutics' Gene Therapy Faces Safety Concerns, Analysts Remain Optimistic

Intellia Therapeutics' stock plummeted in premarket trading after details emerged of a grade 4 adverse event in its phase 3 trial of the gene therapy nex-z. However, despite the setback, analysts are confident in the treatment's wider safety profile, particularly in its ability to knock down the transthyretin protein. The company has reported that the adverse event, classified as grade 4, was asymptomatic and identified through laboratory tests, and that the individual's liver enzyme levels have since returned to grade 3 and 2. Analysts at William Blair expressed disappointment but still believe in the treatment's potential, citing its impressive TTR knockdown profile and de-risking a positive clinical outcome.

Key Takeaways:

• Intellia Therapeutics' stock dropped 23% in premarket trading after a grade 4 adverse event was reported in its phase 3 trial of nex-z.
• The adverse event, which occurred in a patient with transthyretin amyloid cardiomyopathy (ATTR-CM), was asymptomatic and identified through laboratory tests.
• The patient's liver enzyme levels have since returned to grade 3 and 2, the most current classification.
• Analysts at William Blair expressed disappointment but still believe in the treatment's potential, citing its impressive TTR knockdown profile and de-risking a positive clinical outcome.
• Intellia's plan remains to submit an approval application to the FDA for nex-z in transthyretin amyloid polyneuropathy (ATTRv-PN) in 2028 with an anticipated U.S. commercial launch in 2029.
• The company is currently running phase 3 trials in both ATTRv-PN and hereditary angioedema indications.

Statistics:

• 23% - The percentage drop in Intellia's stock in premarket trading.
• More than 200 patients - The number of patients dosed in the phase 3 trial of nex-z in ATTR-CM to date.
• 2028 - The year in which Intellia plans to submit an approval application to the FDA for nex-z in ATTRv-PN.
• 2029 - The anticipated year of U.S. commercial launch for nex-z in ATTRv-PN.

Sources:

• Intellia Therapeutics' May 28 update on its phase 3 trial of nex-z.
• William Blair analysts' May 29 note.
• Company filing.